BYSI - Why BeyondSpring Stock Is Soaring This Week
Shares of BeyondSpring (NASDAQ: BYSI) , a clinical-stage biotech company, have been surging this week in response to a lucrative new partnership with Jiangsu Hengrui Pharmaceuticals in China. Investors are justifiably excited about the partners' new agreement to commercialize and co-develop BeyondSpring's neutropenia-prevention candidate, called plinabulin.
By the time U.S. markets closed on Thursday, BeyondSpring's stock price had already climbed 49.4% from its closing price last Friday.
Chemotherapy kills cancer cells when it catches them trying to divide, but the ubiquitous class of treatments also makes it hard for bone marrow to produce enough white blood cells. This is why a granulocyte colony-stimulating factor G-CSF treatment from Amgen (NASDAQ: AMGN) called Neulasta was able to generate more than $2 billion in sales last year despite launching way back in 2002.
For further details see:
Why BeyondSpring Stock Is Soaring This Week